PhD defences 2016

Tim Kanters
Health Technology Assessment Of Orphan Drugs:
The example of Pompe disease
8 December 2016

Leander Buisman
Early Cost-Effectiveness of Medical Tests in Rheumatoid Arthritis and Ischemic Stroke
30 June 2016

Femke Vennik
Interacting Patients:
The construction of active patientship in quality improvement initiatives
24 June 2016

David Rappange
Future Health:
a policy and an individual perspective
19 May 2016

Liesbeth Lawerman - de Wetering
Valuing and Refining Outcome Measures for Economic Evaluations in Health Care
12 May 2016

Wameq Raza
Evaluations of Social Safety-nets in Bangladesh and India
28 April 2016

Suzanne H.C.M. van Veen
Evaluating and Improving the Predictive Performance of Risk Equalization Models in Health Insurance Markets
7 April 2016

Hedwig Maria Sluimer-Blommestein
The Added Value of Real-World Evidence
1 April 2016

Shamiso Zinzombe
The right to health, pharmaceutical corporations and intellectual property: access to medicine
3 March 2016

Angelica Sousa Fragoso
The relation between the health workforce distribution and maternal and child health inequalities
6 January 2016